Daiichi Sankyo Company

Cuorips Inc. is a medical care company based in Chuo, Japan, with an additional office in Osaka. Founded in 2017, the company focuses on the research, development, and commercialization of iPS cell-derived cardiomyocyte sheets and various cell therapeutic products. Cuorips is involved in the manufacturing and sales of cellular and tissue-based products, as well as providing contract development and manufacturing services. The company aims to advance medical treatments through innovative cell products and therapies.

Cuorips Inc. is a medical care company based in Chuo, Japan, with an additional office in Osaka. Founded in 2017, the company focuses on the research, development, and commercialization of iPS cell-derived cardiomyocyte sheets and various cell therapeutic products. Cuorips is involved in the manufacturing and sales of cellular and tissue-based products, as well as providing contract development and manufacturing services. The company aims to advance medical treatments through innovative cell products and therapies.

Im Co.,Ltd. manufactures and sells cosmetics and over-the-counter drugs. The company offers skin care products, including moisturizing lotions and creams, make up removers, face washes, makeup primers with sun protection, and lip moisturizing treatments; and beauty supplements.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Orphan Disease Treatment Institute develops a treatment for Duchenne muscular dystrophy.

Coherus Biosciences is a biopharmaceutical company that specializes in the development, manufacture, and commercialization of biologic therapeutics, with a strong emphasis on oncology and inflammatory diseases. The company is actively engaged in research and development, focusing on process science, analytical characterization, and protein production. Coherus's portfolio includes FDA-approved products such as UDENYCA, a biosimilar of Neulasta, and it plans to launch YUSIMRY, a biosimilar of Humira, in the United States. Additionally, the company is advancing a pipeline of biosimilar candidates across areas such as immunology and ophthalmology, as well as anti-tumor necrosis factor treatments. With a commitment to building an immuno-oncology franchise, Coherus aims to leverage its diversified portfolio to generate revenue and enhance patient access to biologic therapies.

Plexxikon, Inc. is involved in the discovery and development of small molecule pharmaceuticals aimed at treating various human diseases. The company has developed products such as PLX204 for diabetes, PLX4032 for melanoma and colorectal cancer, and PLX5568 kinase inhibitors for conditions including pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. Plexxikon's research encompasses a diverse portfolio of clinical and preclinical programs addressing several therapeutic areas, including metabolic diseases like obesity, oncological conditions such as osteolytic metastatic disease, and central nervous system disorders including multiple sclerosis. Additional areas of focus include inflammation-related diseases, such as systemic lupus erythematosus and inflammatory bowel disease, as well as cardiovascular conditions like hypertension and atherosclerosis.

Ranbaxy Laboratories Limited is a pharmaceutical company established in 1961, specializing in the production of generic medicines and a variety of pharmaceutical products. With a presence in 49 countries and manufacturing facilities in 11, the company serves customers across approximately 125 countries. Ranbaxy's product portfolio includes around 5,000 stock-keeping units (SKUs), which encompass generic pharmaceuticals, branded generics, and active pharmaceutical ingredients (APIs). The company emphasizes research and development, focusing on novel drug delivery systems and new drug discovery in areas such as infectious diseases, metabolic disorders, and oncology. Notably, Ranbaxy is involved in developing oral controlled-release products and pursuing innovative therapies through collaborations with academic institutions. In June 2008, Ranbaxy formed a strategic alliance with Daiichi Sankyo Company Ltd., enhancing its capabilities in the pharmaceutical sector. The company also has a licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product Neuronox, demonstrating its diverse product offerings beyond traditional pharmaceuticals. Through its commitment to providing quality and affordable medications, Ranbaxy continues to play a significant role in the global healthcare landscape.

U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich. Since May 2008 U3 Pharma belongs to DAIICHI Sankyo Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide and no. 3 in Japan. Being part of this global environment, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics.

SymBio Pharmaceuticals Limited is a biopharmaceutical company based in Tokyo, Japan, focused on the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily in the fields of oncology and hematology. The company develops various anti-cancer agents, including Treakisym, which is used to treat non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, and is currently undergoing Phase III trials for relapsed/refractory diffuse large B-cell lymphoma. Additionally, SymBio is working on several other drug formulations, including SyB L-1701, SyB L-1702, and Rigosertib SyB-C-0501, as well as SyB L-1101 and SyB C-1101 for higher-risk myelodysplastic syndromes. The company also has a candidate, SyB V-1901, aimed at treating infectious diseases. SymBio Pharmaceuticals operates primarily in Japan, South Korea, China, Hong Kong, Taiwan, and Singapore.